A pragmatic approach to monitor and evaluate implementation and impact of differentiated <scp>ART</scp> delivery for global and national stakeholders
Peter Ehrenkranz(Gates Foundation), Irum Zaidi(United States Department of State), Anna Grimsrud(International AIDS Society), Daniel Low‐Beer(World Health Organization), Jesus MG Calleja(World Health Organization), Leigh Tally(Centers for Disease Control and Prevention), William Reidy(Columbia University), Miriam Rabkin(Columbia University), Kate Lockwood Harris(Gates Foundation), Nathan Ford(World Health Organization), Annette Reinisch(Global Fund to Fight AIDS, Tuberculosis and Malaria), George K. Siberry(Columbia University Irving Medical Center), Sadhna Patel(Centers for Disease Control and Prevention), Isaac Zulu(Computer Emergency Response Team), Ade Fakoya(British HIV Association), Suzanne L Jed(United States Department of State), Wafaa El‐Sadr(Columbia University Irving Medical Center)
Cited by 21
Related Papers
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987
Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
|The Lancet|2014|930
Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study
|The Journal of Infectious Diseases|2009|649
Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study
|European Journal of Cardiovascular Prevention & Rehabilitation|2010|392